Embecta Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 16.67.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Embecta Corp's Score
Industry at a Glance
Industry Ranking
52 / 205
Overall Ranking
150 / 4521
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Embecta Corp Highlights
StrengthsRisks
Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.08B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 38.36%.
Undervalued
The company’s latest PE is 6.64, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.75M shares, decreasing 0.01% quarter-over-quarter.
Embecta Corp. is a global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. The Company has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It also sells safety insulin syringes. It distributes its products through a variety of channels, including retail, hospitals and pharmacies.